In vitro activity of antimicrobial agents against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon

American Journal of Infection Control

Volumn 33, Issue 3, 2005, Pages 134-136

  Samaha Kfoury, Joumana N ^a   Kanj, Souha S ^a   Araj, George F ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL ENZYME; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; ERTAPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; HEALTH CARE; KLEBSIELLA PNEUMONIAE; LEBANON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 15744381058     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2004.10.006     Document Type: Article

References (13)

1. J.N. Samaha-Kfoury, and G.F. Araj Recent developments in β-lactamases and extended spectrum β-lactamases BMJ 327 2003 1209 1213
2. P.A. Bradford Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat Clin Microbiol Rev 14 2001 933 951
3. G.F. Araj, and S.S. Kanj Current status and changing trends of antimicrobial resistance in Lebanon J Med Liban 48 2000 221 226
4. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing twelfth informational supplement: M100-S12 2002 National Committee for Clinical Laboratory Standards Wayne
5. Kanafani ZA, Mehio-Sibai A, Araj GF, Kanj SS. Epidemiology and risk factors for extended-spectrum β-lactamase producing organisms: a case-control study abstract 3331, 44th ICAAC, October 29-November 2, 2004; Washington, DC.
6. M. Iqbal, I.K. Patel, S.H. Shah, Q. Aim, N. Barney, and Q. Kiani Susceptibility patterns of Escherichia coli: prevalence of multidrug-resistant isolates and extended spectrum β-lactamase phenotype J Pak Med Assoc 52 2002 407 411
7. R.N. Jones, D.J. Biedenbach, and A.C. Gales Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000) Int J Antimicrob Agents 21 2003 1 7
8. T. Spanu, F. Luzzaro, M. Perilli, G. Amicosante, A. Toniolo, and G. Faddo Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriacea in Italy: Implications for resistance to β-lactams and other antimicrobial drugs Antimicrob Agents Chemother 46 2002 196 202
9. T. Nishino Recent trend for the development of new antibacterial agents Nippon Rinsho 60 2002 2216 2224
10. S.S. Kanj, M. Chedid, and G.F. Araj Susceptibility of bacterial isolates to cefepime in comparison to other broad spectrum antimicrobial agents at a tertiary care center in Lebanon J Med Liban 49 2001 13 17
11. D.L. Paterson, W.C. Ko, A.V. Gottberg, J.M. Casellas, L. Mulazimoglu, and K.P. Klugman Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory J Clin Microbiol 39 2001 2206 2212
12. G. Zanetti, F. Bally, G. Greub, J. Garbino, T. Kinge, and D. Lew Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study Antimicrob Agents Chemother 47 2003 3442 3447
13. D.M. Livermore, K.J. Oakton, M.W. Carter, and M. Warner Activity of ertapenem (MK-0826) versus Enterobacteriacea with potent β-lactamases Antimicrob Agents Chemother 45 2001 2831 2837